Cargando…

Low Molecular Weight Heparin: A Practical Approach in Deep Venous Thrombosis in Palliative Care

INTRODUCTION: Deep vein thrombosis (DVT) is one of the many cause of pain in advance cases of carcinoma cervix. The most widely used agent for combating DVT is unfractionated heparin. AIMS: Aims of this study is to see the efficacy of the use of low molecular weight (LMW) haparin and its practical u...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dutta, Samrat, Chattopadhayay, Subrata, Dasgupta, C, Sarkar, Shyamal
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Medknow Publications 2011
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3183604/ https://www.ncbi.nlm.nih.gov/pubmed/21976855 http://dx.doi.org/10.4103/0973-1075.84536

Ejemplares similares

The efficacy and safety of low-molecular-weight heparin and unfractionated heparin in the treatment of cerebral venous sinus thrombosis
por: Afshari, Daryoush, et al.
Publicado: (2015)

Safety and Feasibility of Subcutaneous Low Molecular Weight Heparin for Cerebral Venous Sinus Thrombosis
por: Kim, Ji Seon, et al.
Publicado: (2005)

Effects of Natural Hirudin and Low Molecular Weight Heparin in Preventing Deep Venous Thrombosis in Aged Patients with Intertrochanteric Fracture
por: Zhang, Zhengdong, et al.
Publicado: (2018)

Efficacy of Low Molecular Weight Heparin in Preventing Perinatal Venous Thrombosis: A Meta-Analysis
por: Huang, Yan, et al.
Publicado: (2022)

Comparison of Apixaban and Low Molecular Weight Heparin in Preventing Deep Venous Thrombosis after Total Knee Arthroplasty in Older Adults
por: Jiang, Hui, et al.
Publicado: (2019)

Feasibility of anticoagulation using low molecular-weight heparin during catheter-directed thrombolysis for lower extremity deep venous thrombosis
por: Li, Yonghui, et al.
Publicado: (2021)

Low molecular weight heparin versus unfractionated heparin in the management of cerebral venous thrombosis: A systematic review and meta-analysis
por: Qureshi, Anjum, et al.
Publicado: (2017)

Low-molecular-weight heparins in the treatment of venous thromboembolism
por: Ageno , Walter, et al.
Publicado: (2000)

Why differentiate low molecular weight heparins for venous thromboembolism?
por: Fareed, Jawed, et al.
Publicado: (2007)

The anticoagulants rivaroxaban and low molecular weight heparin prevent PICC-related upper extremity venous thrombosis in cancer patients
por: Lv, Shoutian, et al.
Publicado: (2019)

Cancer-Associated Venous Thromboembolism: A Practical Review Beyond Low-Molecular-Weight Heparins
por: Smrke, Alannah, et al.
Publicado: (2017)

Biomarkers of Venous Thromboembolism Recurrence after Discontinuation of Low Molecular Weight Heparin Treatment for Cancer-Associated Thrombosis (HISPALIS-Study)
por: Otero, Remedios, et al.
Publicado: (2022)

Low molecular weight heparin in prophylaxis of deep vein thrombosis in Asian general surgical patients: A Kashmir experience
por: Dar, Tanveer Iqbal, et al.
Publicado: (2012)

Risk factors for deep vein thrombosis even using low-molecular-weight heparin after total knee arthroplasty
por: Lee, Joon Kyu, et al.
Publicado: (2021)

The Promising Future of Low-Molecular-Weight Heparin in Pediatric Cerebral Venous Sinus Thrombosis Occurring as a Rare Complication of Ulcerative Colitis
por: Yaqoob, Sadia, et al.
Publicado: (2021)

Two Pediatric Patients with Splanchnic Venous Thrombosis as a Complication of Acute Pancreatitis Successfully Treated with Low-Molecular-Weight Heparin and Rivaroxaban
por: Capraro, Shannon, et al.
Publicado: (2022)

Safety and efficacy of low-molecular-weight heparins in prophylaxis of deep vein thrombosis in postoperative/ICU patients: A comparative study
por: Saxena, Arpita, et al.
Publicado: (2013)

Unfractionated heparin or low-molecular-weight heparin for venous thromboembolism prophylaxis after hepatic resection: A meta-analysis
por: Zhang, Wentao, et al.
Publicado: (2022)

Rivaroxaban versus Low-Molecular-Weight Heparin for Venous Thromboembolism in Gastrointestinal and Pancreatobiliary Cancer
por: Lee, Jang Ho, et al.
Publicado: (2019)

Effectiveness and Safety of Rivaroxaban and Low Molecular Weight Heparin in Cancer-Associated Venous Thromboembolism
por: Coleman, Craig I., et al.
Publicado: (2023)

Cancer-associated thrombosis, low-molecular-weight heparin, and the patient experience: a qualitative study
por: Seaman, Siwan, et al.
Publicado: (2014)

Low Molecular Weight Heparin in Portal Vein Thrombosis of Cirrhotic Patients: Only Therapeutic Purposes?
por: Licinio, Raffaele, et al.
Publicado: (2014)

Evaluation of Low-Molecular-Weight Heparin for Treatment of Portal Vein Thrombosis in Liver Cirrhosis Patients
por: Han, Ji Min, et al.
Publicado: (2023)

Unfractionated and low molecular weight heparin
por: Lima, Marcelo, et al.
Publicado: (2014)

Combination of Traditional Chinese Medicine and Low-Molecular-Weight Heparin Prevents Deep Vein Thrombosis After Surgery: A Meta-Analysis
por: Chen, Chu, et al.
Publicado: (2019)

Heparin/low molecular weight heparins: Thrombocytopenia: 7 case reports
Publicado: (2021)

Extensive Thrombosis in a Severe COVID-19 Patient Despite Prophylactic Low Molecular Weight Heparin
por: Elkattawy, Sherif, et al.
Publicado: (2020)

Application of low molecular weight heparins in umbilical artery thrombosis: A case series and review of the literature
por: Wang, Ting, et al.
Publicado: (2023)

The therapeutic efficacy and safety of traditional Chinese medicine injection combined with low-molecular-weight heparin on the acute lower extremity deep venous thrombosis: A protocol for systematic review and network meta-analysis
por: Zeng, Mulan, et al.
Publicado: (2021)

Arterial indications for the low molecular weight heparins
por: Ageno, Walter, et al.
Publicado: (2001)

Low Dose Low-Molecular-Weight Heparin for Thrombosis Prophylaxis: Systematic Review with Meta-Analysis and Trial Sequential Analysis
por: Eck, Ruben J., et al.
Publicado: (2019)

Prevention and treatment of venous thromboembolism with low-molecular-weight heparins: Clinical implications of the recent European guidelines
por: Prandoni, Paolo
Publicado: (2008)

Prophylaxis of cancer-associated venous thromboembolism with low-molecular-weight heparin-tinzaparin: Real world evidence
por: Christopoulou, Athina, et al.
Publicado: (2022)

Effect of heparin and low-molecular weight heparin on serum potassium and sodium levels
por: Bengalorkar, Girish M., et al.
Publicado: (2011)

Comparison of Low-Molecular-Weight Heparins Prepared From Ovine Heparins With Enoxaparin
por: Chen, Jianle, et al.
Publicado: (2019)

Cancer-Associated Thrombosis: Not All Low-Molecular-Weight Heparins Are the Same, Focus on Tinzaparin, A Narrative Review
por: Fioretti, Agnese Maria, et al.
Publicado: (2022)

The effect of low molecular weight heparin combined with air pressure in the prevention of lower extremity venous thrombosis after cesarean section: A single-center retrospective study
por: Guo, Jian, et al.
Publicado: (2023)

Anticoagulant management by low-dose of low molecular weight heparin in patients with nonvalvular atrial fibrillation following hemorrhagic transformation and complicated with venous thrombosis: Five case reports and literature review
por: Zhang, Ling, et al.
Publicado: (2021)

Arterial and Venous Thrombosis From Delayed-Onset Heparin-Induced Thrombocytopenia
por: Chittal, Abhinandan R., et al.
Publicado: (2022)

Unilateral digital arterial ligation combined with low molecular weight heparins in severed finger without venous anastomosis
por: Chen, Xueming, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_sra351gnqtgd3m22kfl59ki7jo